La Jolla Pharmaceutical Co

Introduction

La Jolla Pharmaceutical (La Jolla) is a development stage biotechnology company focused entirely on novel antibody therapies for specific autoimmune diseases. The company's only clinical stage candidate, Riquent, is being studied in Phase III trials for the treatment of lupus.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Riquent, a molecule designed to induce B cell tolerance to dsDNA as a treatment for lupus, has already been through a Phase II/III trial and a pivotal Phase III trial, resulting in an approvable letter from the FDA asking for further clinical evidence of the drug's efficacy. La Jolla leverages its proprietary Tolerance Technology to address the underlying causes of life-threatening antibody-mediated diseases. Using this, it discovers and develops novel therapeutics, called Toleragens, designed to suppress the production of specific disease-causing antibodies without affecting the functions of the immune system. La Jolla did not record any revenues during 2002-2006. Currently, the company does not have any collaboration agreement. Future performance of the company is highly reliant on Riquent which is subject to regulatory approvals.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .